For: | Weinstein AA, De Avila L, Kannan S, Paik JM, Golabi P, Gerber LH, Younossi ZM. Interrelationship between physical activity and depression in nonalcoholic fatty liver disease. World J Hepatol 2022; 14(3): 612-622 [PMID: 35582293 DOI: 10.4254/wjh.v14.i3.612] |
---|---|
URL: | https://www.wjgnet.com/1948-5182/full/v14/i3/612.htm |
Number | Citing Articles |
1 |
Derek D. Satre, Dhweeja Dasarathy, Steven L. Batki, Michael J. Ostacher, Hannah R. Snyder, William Hua, Priti Parekh, Amy M. Shui, Ramsey Cheung, Alexander Monto, Robert J. Wong, Jennifer Y. Chen, Meimei Liao, Michele Tana, Po‐Hung Chen, Christina G. Haight, Taylor Fakadej, Mandana Khalili. Factors Associated With Motivation to Reduce Alcohol Use Among Patients With Chronic Liver Disease. Alimentary Pharmacology & Therapeutics 2024; doi: 10.1111/apt.18387
|
2 |
Lucia Brodosi, Michele Stecchi, Alessandra Musio, Matilde Bazzocchi, Eleonora Risi, Francesca Marchignoli, Giulio Marchesini, Maria Letizia Petroni. Anxiety and depression in metabolic-associated steatotic liver disease: relation with socio-demographic features and liver disease severity. Acta Diabetologica 2024; 61(8): 1041 doi: 10.1007/s00592-024-02287-0
|
3 |
Cheng Han Ng, Zhen Yu Wong, Nicholas W. S. Chew, Kai En Chan, Jieling Xiao, Nilofer Sayed, Wen Hui Lim, Darren Jun Hao Tan, Ryan Wai Keong Loke, Phoebe Wen Lin Tay, Jie Ning Yong, Gywneth Kong, Daniel Q. Huang, Jiong-Wei Wang, Mark Chan, Mayank Dalakoti, Nobuharu Tamaki, Mazen Noureddin, Mohammad Shadab Siddiqui, Arun J. Sanyal, Mark Muthiah. Hypertension is prevalent in non-alcoholic fatty liver disease and increases all-cause and cardiovascular mortality. Frontiers in Cardiovascular Medicine 2022; 9 doi: 10.3389/fcvm.2022.942753
|
4 |
Aybuke Sapmaz, Annette Paik, Linda Henry, Zobair M. Younossi. A comprehensive review of patient-reported outcomes in metabolic dysfunction-associated steatotic liver disease. Metabolism and Target Organ Damage 2024; 4(4) doi: 10.20517/mtod.2024.70
|
5 |
Zobair M. Younossi, Linda Henry. Understanding the Burden of Nonalcoholic Fatty Liver Disease: Time for Action. Diabetes Spectrum 2024; 37(1): 9 doi: 10.2337/dsi23-0010
|